8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
Apr 13, 2026·SEC
IDEAYA Biosciences, Inc.(IDYA)Earnings, Financials & Key Ratios
IDYA•NASDAQ
$28.74
$2.52B mkt cap·Price updated May 6, 2026
AboutIDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Show more
- Revenue$219M+3024.4%
- EBITDA-$155M+52.1%
- Net Income-$114M+58.6%
- EPS (Diluted)-1.28+61.9%
- Gross Margin97.9%+116.5%
- EBITDA Margin-70.74%+98.5%
- Operating Margin-72.84%+98.4%
- Net Margin-51.99%+98.7%
- ROE-10.92%+66.6%
- ROIC-12.37%+63.2%
- Debt/Equity0.03+50.8%
IDYA Key Insights
IDEAYA Biosciences, Inc. (IDYA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 62.1%
✗Weaknesses
- ✗Profits declining 26.9% over 5 years
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
IDYA Price & Volume
IDEAYA Biosciences, Inc. (IDYA) stock price & volume — 10-year historical chart
Loading chart...
IDYA Growth Metrics
IDEAYA Biosciences, Inc. (IDYA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years62.11%
3 Years62.54%
TTM3118.14%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM54.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM55.43%
Return on Capital
10 Years-38.29%
5 Years-23.17%
3 Years-26.97%
Last Year-14.97%
IDYA Recent Earnings
IDEAYA Biosciences, Inc. (IDYA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 5/12 qtrs (71%)
Q2 2026Latest
May 5, 2026EPS
$1.11
Est $1.01
-10.3%
Revenue
$7M
Est $5M
+30.2%
Q1 2026
Feb 17, 2026EPS
$0.94
Est $0.95
+1.2%
Revenue
$11M
Est $6M
+72.5%
Q4 2025
Nov 4, 2025EPS
$1.33
Est $0.95
+240.6%
Revenue
$208M
Est $6M
+3395.1%
Q3 2025
Aug 5, 2025EPS
$0.88
Est $0.85
-3.5%
Revenue
—
Est $2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.11vs $1.01-10.3% | $7Mvs $5M+30.2% |
| Q1 2026 | Feb 17, 2026 | $0.94vs $0.95+1.2% | $11Mvs $6M+72.5% |
| Q4 2025 | Nov 4, 2025 | $1.33vs $0.95+240.6% | $208Mvs $6M+3395.1% |
| Q3 2025 | Aug 5, 2025 | $0.88vs $0.85-3.5% | —vs $2M |
Based on last 12 quarters of dataView full earnings history →
IDYA Peer Comparison
IDEAYA Biosciences, Inc. (IDYA) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TPVG | 225.54M | 5.57 | 4.57 | 36.55% | 13.09% | 1.33 | ||
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 PMVP | 76.84M | 1.45 | -1.27 | -55.34% | 0.01 | |||
 TNGX | 3.21B | 23.62 | -27.15 | 48.29% | -162.85% | -50.3% | 0.10 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 |
Compare IDYA vs Peers
IDEAYA Biosciences, Inc. (IDYA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IDYA Income Statement
IDEAYA Biosciences, Inc. (IDYA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 19.54M | 27.94M | 50.93M | 23.39M | 7M | 218.71M | 225.27M |
| Revenue Growth % | - | - | - | - | 43.01% | 82.28% | -54.08% | -70.07% | 3024.43% | 3118.14% |
| Cost of Goods Sold | 391K | 886K | 1.25M | 1.38M | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M | 0 |
| COGS % of Revenue | - | - | - | 7.07% | 6.17% | 4.13% | 17.14% | 54.77% | 2.1% | - |
| Gross Profit | -391K▲ 0% | -886K▼ 126.6% | -1.25M▼ 40.5% | 18.16M▲ 1558.4% | 26.22M▲ 44.4% | 48.83M▲ 86.3% | 19.38M▼ 60.3% | 3.17M▼ 83.7% | 214.12M▲ 6663.0% | 218.71M▲ 0% |
| Gross Margin % | - | - | - | 92.93% | 93.83% | 95.87% | 82.86% | 45.23% | 97.9% | 97.09% |
| Gross Profit Growth % | - | -126.6% | -40.52% | 1558.39% | 44.39% | 86.26% | -60.32% | -83.66% | 6663.01% | - |
| Operating Expenses | 14.05M | 35.53M | 43.03M | 53.5M | 76.48M | 111.33M | 153.81M | 330.14M | 373.43M | 408.74M |
| OpEx % of Revenue | - | - | - | 273.83% | 273.73% | 218.59% | 657.71% | 4716.3% | 170.74% | - |
| Selling, General & Admin | 1.66M | 3.78M | 8.71M | 13.8M | 18.33M | 21.8M | 24.3M | 35.47M | 63.32M | 69.19M |
| SG&A % of Revenue | - | - | - | 70.65% | 65.59% | 42.8% | 103.9% | 506.69% | 28.95% | - |
| Research & Development | 12.38M | 31.75M | 34.32M | 39.7M | 58.16M | 89.54M | 129.51M | 294.67M | 314.7M | 339.54M |
| R&D % of Revenue | - | - | - | 203.18% | 208.15% | 175.8% | 553.81% | 4209.61% | 143.89% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.59M | 0 |
| Operating Income | -14.44M▲ 0% | -36.42M▼ 152.2% | -44.27M▼ 21.6% | -35.34M▲ 20.2% | -50.27M▼ 42.2% | -62.5M▼ 24.3% | -134.43M▼ 115.1% | -326.98M▼ 143.2% | -159.31M▲ 51.3% | -183.47M▲ 0% |
| Operating Margin % | - | - | - | -180.9% | -179.91% | -122.72% | -574.85% | -4671.07% | -72.84% | -81.44% |
| Operating Income Growth % | - | -152.23% | -21.57% | 20.16% | -42.23% | -24.34% | -115.08% | -143.23% | 51.28% | - |
| EBITDA | -14.05M | -35.53M | -43.03M | -33.96M | -48.54M | -60.4M | -130.42M | -323.14M | -154.72M | -180.01M |
| EBITDA Margin % | - | - | - | -173.83% | -173.73% | -118.59% | -557.71% | -4616.3% | -70.74% | -79.91% |
| EBITDA Growth % | - | -152.94% | -21.09% | 21.06% | -42.93% | -24.43% | -115.93% | -147.77% | 52.12% | 49.5% |
| D&A (Non-Cash Add-back) | 391K | 886K | 1.25M | 1.38M | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M | 3.46M |
| EBIT | -11.86M | -34.35M | -41.98M | -34.49M | -49.76M | -58.66M | -112.96M | -274.48M | -159.31M | -74.92M |
| Net Interest Income | 150K | 1.99M | 2.29M | 849K | 506K | 3.85M | 21.47M | 52.5M | 45.62M | 33.4M |
| Interest Income | 150K | 1.99M | 2.29M | 849K | 506K | 3.85M | 21.47M | 52.5M | 45.62M | 33.4M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 2.58M | 2.07M | 2.3M | 849K | 506K | 3.85M | 21.47M | 52.5M | 45.62M | 43.41M |
| Pretax Income | -11.86M▲ 0% | -34.35M▼ 189.5% | -41.98M▼ 22.2% | -34.49M▲ 17.8% | -49.76M▼ 44.3% | -58.66M▼ 17.9% | -112.96M▼ 92.6% | -274.48M▼ 143.0% | -113.7M▲ 58.6% | -140.06M▲ 0% |
| Pretax Margin % | - | - | - | -176.55% | -178.1% | -115.17% | -483.05% | -3921.1% | -51.99% | -62.17% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -11.86M▲ 0% | -34.35M▼ 189.5% | -41.98M▼ 22.2% | -34.49M▲ 17.8% | -49.76M▼ 44.3% | -58.66M▼ 17.9% | -112.96M▼ 92.6% | -274.48M▼ 143.0% | -113.7M▲ 58.6% | -140.06M▲ 0% |
| Net Margin % | - | - | - | -176.55% | -178.1% | -115.17% | -483.05% | -3921.1% | -51.99% | -62.17% |
| Net Income Growth % | - | -189.55% | -22.21% | 17.82% | -44.26% | -17.87% | -92.59% | -142.98% | 58.58% | 54.28% |
| Net Income (Continuing) | -11.86M | -34.35M | -41.98M | -34.49M | -49.76M | -58.66M | -112.96M | -274.48M | -113.7M | -140.06M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.83▲ 0% | -2.41▼ 190.4% | -1.90▲ 21.2% | -1.31▲ 31.1% | -1.41▼ 7.6% | -1.42▼ 0.7% | -1.96▼ 38.0% | -3.36▼ 71.4% | -1.28▲ 61.9% | -1.58▲ 0% |
| EPS Growth % | - | -190.36% | 21.16% | 31.05% | -7.63% | -0.71% | -38.03% | -71.43% | 61.9% | 55.43% |
| EPS (Basic) | -0.83 | -2.41 | -1.90 | -1.31 | -1.41 | -1.42 | -1.96 | -3.36 | -1.28 | - |
| Diluted Shares Outstanding | 14.24M | 14.24M | 20.23M | 24.72M | 35.25M | 41.44M | 57.52M | 81.68M | 88.49M | 88.7M |
| Basic Shares Outstanding | 14.24M | 14.24M | 20.23M | 24.72M | 35.25M | 41.44M | 57.52M | 81.68M | 88.49M | 88.7M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
IDYA Balance Sheet
IDEAYA Biosciences, Inc. (IDYA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 13.58M | 90.67M | 101.65M | 288.61M | 251M | 370.45M | 532.63M | 689.71M | 666.73M | 696.11M |
| Cash & Short-Term Investments | 13.16M | 89.96M | 98.96M | 283.58M | 246.77M | 364.83M | 525.11M | 676.32M | 639.39M | 671.2M |
| Cash Only | 5.96M | 20.5M | 34.07M | 72.04M | 92.05M | 68.63M | 157.02M | 84.38M | 112.83M | 157.52M |
| Short-Term Investments | 7.2M | 69.46M | 64.89M | 211.55M | 154.72M | 296.2M | 368.1M | 591.94M | 526.56M | 513.68M |
| Accounts Receivable | 0 | 0 | 0 | 1.88M | 1.1M | 211K | 18K | 3K | 0 | 0 |
| Days Sales Outstanding | - | - | - | 35.07 | 14.41 | 1.51 | 0.28 | 0.16 | - | 2.42 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 5.41M | 7.5M | 13.39M | 27.34M | 24.91M |
| Total Non-Current Assets | 3.9M | 5.87M | 11.35M | 9.66M | 130.35M | 17.52M | 116.68M | 434.38M | 442.6M | 334.24M |
| Property, Plant & Equipment | 3.74M | 5.15M | 9.7M | 9.48M | 8.66M | 8.99M | 8.41M | 27.74M | 31.29M | 31.25M |
| Fixed Asset Turnover | - | - | - | 2.06x | 3.23x | 5.66x | 2.78x | 0.25x | 6.99x | 7.10x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 71K | 0 | 1.53M | 0 | 121.29M | 8.32M | 107.49M | 405.83M | 0 | 1.08B |
| Other Non-Current Assets | 89K | 722K | 122K | 188K | 397K | 205K | 782K | 805K | 411.31M | 304.6M |
| Total Assets | 17.48M▲ 0% | 96.54M▲ 452.3% | 113M▲ 17.0% | 298.27M▲ 164.0% | 381.35M▲ 27.9% | 387.97M▲ 1.7% | 649.32M▲ 67.4% | 1.12B▲ 73.1% | 1.11B▼ 1.3% | 1.03B▲ 0% |
| Asset Turnover | - | - | - | 0.07x | 0.07x | 0.13x | 0.04x | 0.01x | 0.20x | 0.21x |
| Asset Growth % | - | 452.33% | 17.05% | 163.95% | 27.85% | 1.74% | 67.36% | 73.12% | -1.31% | -5.17% |
| Total Current Liabilities | 2.43M | 5.41M | 6.94M | 38.64M | 45.16M | 31.72M | 27.1M | 46.07M | 58.81M | 64.83M |
| Accounts Payable | 662K | 1.42M | 709K | 953K | 2.1M | 4.28M | 6.6M | 15.42M | 17.58M | 20.74M |
| Days Payables Outstanding | 617.98 | 583.75 | 207.86 | 251.88 | 444.35 | 743.55 | 600.87 | 1.47K | 1.4K | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 339K | 350K |
| Deferred Revenue (Current) | 297K | 0 | 0 | 27.61M | 29.04M | 8.57M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 728K | 413K | 63K | 18K | 0 | 0 | 11.78M | 30.35M | 40.89M | 43.74M |
| Current Ratio | 5.58x | 16.75x | 14.65x | 7.47x | 5.56x | 11.68x | 19.65x | 14.97x | 11.34x | 11.34x |
| Quick Ratio | 5.58x | 16.75x | 14.65x | 7.47x | 5.56x | 11.68x | 19.65x | 14.97x | 11.34x | 11.34x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 2.42 |
| Total Non-Current Liabilities | 30.78M | 140.08M | 5.66M | 61.35M | 34.67M | 6.8M | 1.13M | 18.87M | 27.57M | 28.25M |
| Long-Term Debt | 3.21M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27.57M | 28.25M |
| Capital Lease Obligations | 0 | 0 | 5.63M | 5.18M | 3.48M | 1.61M | 1.13M | 18.87M | 0 | 80.77M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 27.58M | 140.08M | 34K | 12K | 0 | 0 | 0 | 0 | 0 | -25.9M |
| Total Liabilities | 33.22M | 145.49M | 12.6M | 100M | 79.83M | 38.51M | 28.23M | 64.94M | 86.39M | 93.08M |
| Total Debt | 3.21M | 0 | 6.77M | 6.72M | 5.18M | 3.48M | 2.87M | 19.17M | 27.91M | 28.6M |
| Net Debt | -2.75M | -20.5M | -27.3M | -65.31M | -86.86M | -65.15M | -154.15M | -65.21M | -84.91M | -128.92M |
| Debt / Equity | - | - | 0.07x | 0.03x | 0.02x | 0.01x | 0.00x | 0.02x | 0.03x | 0.03x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.16x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.72x |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | -15.74M▲ 0% | -48.95M▼ 211.0% | 100.4M▲ 305.1% | 198.27M▲ 97.5% | 301.51M▲ 52.1% | 349.45M▲ 15.9% | 621.09M▲ 77.7% | 1.06B▲ 70.5% | 1.02B▼ 3.4% | 937.27M▲ 0% |
| Equity Growth % | - | -211% | 305.12% | 97.48% | 52.07% | 15.9% | 77.73% | 70.53% | -3.42% | -16.38% |
| Book Value per Share | -1.11 | -3.44 | 4.96 | 8.02 | 8.55 | 8.43 | 10.80 | 12.97 | 11.56 | 10.57 |
| Total Shareholders' Equity | -15.74M | -48.95M | 100.4M | 198.27M | 301.51M | 349.45M | 621.09M | 1.06B | 1.02B | 937.27M |
| Common Stock | 1K | 0 | 2K | 3K | 4K | 5K | 7K | 9K | 9K | 9K |
| Retained Earnings | -16.17M | -50.52M | -92.49M | -126.99M | -176.75M | -235.4M | -348.36M | -622.84M | -736.54M | -835.08M |
| Treasury Stock | -431K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1K | -31K | 65K | 7K | -712K | -2.87M | 562K | 812K | 2.27M | -494K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IDYA Cash Flow Statement
IDEAYA Biosciences, Inc. (IDYA) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.22M | -27.62M | -39.31M | 55.46M | -55.78M | -87.17M | -115.22M | -247.58M | -71.1M | -71.1M |
| Operating CF Margin % | - | - | - | 283.87% | -199.63% | -171.16% | -492.73% | -3536.91% | -32.51% | - |
| Operating CF Growth % | - | -125.95% | -42.34% | 241.08% | -200.57% | -56.29% | -32.18% | -114.87% | 71.28% | 424.47% |
| Net Income | -11.86M | -34.35M | -41.98M | -34.49M | -49.76M | -58.66M | -112.96M | -274.48M | -113.7M | -140.06M |
| Depreciation & Amortization | 391K | 886K | 1.25M | 1.38M | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M | 3.46M |
| Stock-Based Compensation | 136K | 950K | 2.17M | 3.61M | 8.24M | 11.63M | 18.49M | 34.75M | 0 | 24.09M |
| Deferred Taxes | -27K | -873K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -2.43M | 4.11M | -467K | 562K | 1.83M | -695K | -11.55M | -23.23M | 36.14M | 104.13M |
| Working Capital Changes | 1.56M | 1.65M | -284K | 84.41M | -17.81M | -41.55M | -13.21M | 11.55M | 1.87M | -2.38M |
| Change in Receivables | 0 | 0 | 0 | -1.88M | 774K | 892K | 193K | 15K | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 2.29M | 3.79M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 254K | 322K | -195K | 225K | 1.17M | 1.86M | 2.63M | 8.28M | 2.7M | -31K |
| Cash from Investing | -8.93M | -63.18M | 2.27M | -146.24M | -69.67M | -33.4M | -158.46M | -502.56M | 69.98M | -9.84M |
| Capital Expenditures | -1.76M | -1.71M | -1.35M | -493K | -2.64M | -3.44M | -2.37M | -3.86M | -2.37M | -1.04M |
| CapEx % of Revenue | - | - | - | 2.52% | 9.46% | 6.76% | 10.13% | 55.1% | 1.08% | - |
| Acquisitions | 0 | 0 | -8K | -18K | 67.02M | 33.4M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 8K | 18K | -67.02M | -33.4M | 0 | 0 | 0 | 0 |
| Cash from Financing | 17.49M | 105.38M | 50.61M | 128.75M | 145.45M | 97.17M | 362.72M | 677.55M | 29.78M | 3.64M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 17.26M | 105.36M | 50.32M | 127.23M | 143.25M | 94.96M | 351.94M | 663.63M | 29.78M | 3.64M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 226K | 20K | 289K | 1.52M | 2.2M | 2.2M | 10.77M | 13.92M | 0 | 0 |
| Net Change in Cash | -3.66M▲ 0% | 14.58M▲ 498.2% | 13.56M▼ 7.0% | 37.97M▲ 180.0% | 20.01M▼ 47.3% | -23.41M▼ 217.0% | 89.04M▲ 480.3% | -72.59M▼ 181.5% | 28.45M▲ 139.2% | -130M▲ 0% |
| Free Cash Flow | -13.98M▲ 0% | -29.33M▼ 109.8% | -40.67M▼ 38.7% | 54.97M▲ 235.2% | -58.42M▼ 206.3% | -90.62M▼ 55.1% | -117.59M▼ 29.8% | -251.44M▼ 113.8% | -73.47M▲ 70.8% | -11.79M▲ 0% |
| FCF Margin % | - | - | - | 281.35% | -209.09% | -177.92% | -502.85% | -3592.01% | -33.59% | -5.24% |
| FCF Growth % | - | -109.77% | -38.66% | 235.17% | -206.28% | -55.11% | -29.77% | -113.82% | 70.78% | 95.6% |
| FCF per Share | -0.98 | -2.06 | -2.01 | 2.22 | -1.66 | -2.19 | -2.04 | -3.08 | -0.83 | -0.83 |
| FCF Conversion (FCF/Net Income) | 1.03x | 0.80x | 0.94x | -1.61x | 1.12x | 1.49x | 1.02x | 0.90x | 0.63x | 0.08x |
| Interest Paid | 0 | 99K | 91K | 82K | 71K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 1K | 1K | 1K | 4K | 0 | 0 | 0 | 0 | 0 |
IDYA Key Ratios
IDEAYA Biosciences, Inc. (IDYA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -163.16% | -23.1% | -19.91% | -18.02% | -23.28% | -32.67% | -10.92% | -13.96% |
| Return on Invested Capital (ROIC) | - | -1818.36% | -25.73% | -21.69% | -18.79% | -26.84% | -33.57% | -12.37% | -12.37% |
| Gross Margin | - | - | 92.93% | 93.83% | 95.87% | 82.86% | 45.23% | 97.9% | 97.09% |
| Net Margin | - | - | -176.55% | -178.1% | -115.17% | -483.05% | -3921.1% | -51.99% | -62.17% |
| Debt / Equity | - | 0.07x | 0.03x | 0.02x | 0.01x | 0.00x | 0.02x | 0.03x | 0.03x |
| FCF Conversion | 0.80x | 0.94x | -1.61x | 1.12x | 1.49x | 1.02x | 0.90x | 0.63x | 0.08x |
| Revenue Growth | - | - | - | 43.01% | 82.28% | -54.08% | -70.07% | 3024.43% | 3118.14% |
IDYA SEC Filings & Documents
IDEAYA Biosciences, Inc. (IDYA) SEC filings — annual & quarterly reports (10-K, 10-Q)
IDYA Frequently Asked Questions
IDEAYA Biosciences, Inc. (IDYA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
IDEAYA Biosciences, Inc. (IDYA) reported $225.3M in revenue for fiscal year 2025.
IDEAYA Biosciences, Inc. (IDYA) grew revenue by 3024.4% over the past year. This is strong growth.
IDEAYA Biosciences, Inc. (IDYA) reported a net loss of $140.1M for fiscal year 2025.
Dividend & Returns
IDEAYA Biosciences, Inc. (IDYA) has a return on equity (ROE) of -10.9%. Negative ROE indicates the company is unprofitable.
IDEAYA Biosciences, Inc. (IDYA) had negative free cash flow of $11.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More IDYA
IDEAYA Biosciences, Inc. (IDYA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates